KRAS and metastatic colorectal cancer: Systemic treatment for metastatic colorectal cancer relies on cytotoxic chemotherapy with the addition of monoclonal antibodies targeting angiogenesis or the tyrosine kinase receptor EGFR for patients with a wild-type KRAS oncogene [5].